Risk factor
Vulnerable to price shocks
Profitability factor
Strong growth
About
Eckert & Ziegler Strahlen- und Medizintechnik AG, along with its various subsidiaries, is a global specialist in the production and delivery of sophisticated isotope technology components. These components are utilized across a broad spectrum of medical, scientific, and industrial applications worldwide. The company operates through two primary divisions: Medical and Isotope Products. The Medical segment focuses on therapeutic radioactive solutions. This includes furnishing tiny radioactive implants, often called 'seeds,' for prostate cancer therapy, as well as developing ocular applicators containing ruthenium-106 or iodine-125 to treat uveal melanoma. Additionally, this division supplies radiopharmaceutical compounds, specialized laboratory equipment, shielded hot cells, and related services for radiopharmaceuticals, in addition to their dedicated eye applicators and prostate implants. The Isotope Products segment is responsible for manufacturing and distributing radiation sources essential for a range of technical processes. These encompass medical imaging, precise measurement systems, material characterization, quality assurance protocols, and environmental surveillance. Furthermore, this division provides calibration sources vital for medical diagnostic imaging systems, alongside products designed for national security purposes and radiometric level sensing. Founded in 1992, the company maintains its corporate headquarters in Berlin, Germany.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair valu
Target Price
The average target price of EUZ.DE is 21 and suggests 38% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa